Library / Peptides / Hormone Optimization / Ipamorelin
Emerging evidence · Grade B

Ipamorelin

Ipamorelin Acetate
Evidence
Emerging
Route
Subcutaneous injection
Frequency
1-3x daily (often before bed)
Category
Hormone Optimization
TL;DR
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively stimulates GH release from the pituitary gland. It is considered the most selective GHRP, producing robust GH release with minimal impact on cortisol, prolactin, and appetite — making it the cleanest GH secretagogue in its class.
Part 01 · How it works

Mechanism.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively stimulates GH release from the pituitary gland. It is considered the most selective GHRP, producing robust GH release with minimal impact on cortisol, prolactin, and appetite — making it the cleanest GH secretagogue in its class. It is one of the most widely prescribed peptides in anti-aging and optimization clinics.

If GHRP-6 is like turning up the volume on your entire stereo system (GH, appetite, cortisol all go up), ipamorelin is like a precision equalizer that only turns up the GH channel, leaving everything else at its normal level.

Mechanism · technical
Ipamorelin binds to the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering growth hormone release in a pulsatile fashion that mimics natural GH secretion patterns. Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly stimulate ACTH/cortisol or prolactin at therapeutic doses, giving it a cleaner hormonal profile. It works synergistically with GHRH analogs (like CJC-1295) — GHRH initiates the GH pulse while ipamorelin amplifies its magnitude.
Part 02 · Dosing & administration

How it's taken.

Values below describe how Ipamorelin has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
200-300 mcg
Subcutaneous injection · 1-3x daily (often before bed)
Duration
8-12 weeks typical cycle

Selective GH secretagogue with minimal effect on cortisol, prolactin, or appetite. Often combined with CJC-1295 (no DAC). Considered the 'cleanest' GHRP. Not FDA-approved.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects
Ipamorelin is generally well tolerated with a favorable side effect profile compared to other GH secretagogues. Reported side effects include mild headache, transient flushing, water retention, and injection site irritation. It does not significantly increase appetite, cortisol, or prolactin at standard doses. Long-term safety data from large controlled trials is limited.
Absolute · do not use
×
Active malignancy or history of cancer
×
Pituitary tumor or hypothalamic disorders
×
Diabetic retinopathy
×
Pregnancy or breastfeeding
×
Children under 18 (unless for diagnosed GH deficiency under specialist care)
×
Known hypersensitivity to ipamorelin or any component
Interactions
Insulin
GH secretagogues can increase insulin resistance; may require insulin dose adjustment
Major
Oral hypoglycemics
GH elevation may counteract glucose-lowering effects; monitor blood glucose
Moderate
Corticosteroids
Chronic corticosteroid use blunts GH release and may reduce ipamorelin efficacy
Moderate
Somatostatin analogs (octreotide)
Directly antagonizes GH release stimulated by ipamorelin
Major
Labs to monitor
IGF-1
Baseline, 4 weeks, then every 3 months
Monitor growth hormone axis stimulation
Fasting Glucose & Insulin
Baseline and monthly
GH can impair insulin sensitivity
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
CBC with Differential
Baseline and every 3 months
General safety monitoring
Part 04 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

01
1998
0
Ipamorelin, the first selective growth hormone secretagogue
Ipamorelin selectively released GH without affecting ACTH, cortisol, prolactin, or FSH/LH levels
Preclinical study establishing selectivity; well-cited
PMID 9849822 ↗
02
2008
0
Safety and efficacy of ipamorelin for postoperative ileus
Ipamorelin showed GI prokinetic effects and was well-tolerated in surgical patients
Phase II RCT; GI indication rather than GH focus
Part 05 · Cost & access

Where you can get it.

Regulatory status
Ipamorelin is not FDA-approved for any indication. It is available through compounding pharmacies with a prescription and is one of the most commonly prescribed peptides in optimization medicine. It is prohibited by WADA in competitive sports.
The Peptide Column takes no affiliate commission from any source.
Part 06 · Your appointment

Questions to bring.

01
Is ipamorelin alone sufficient, or should it be combined with CJC-1295?
02
What is the optimal timing for ipamorelin injections relative to meals and sleep?
03
What baseline and follow-up labs (IGF-1, metabolic panel) should I monitor?
04
How long does it take to see results from ipamorelin?
05
Is there a risk of pituitary desensitization with long-term use?
06
How does ipamorelin compare to direct GH replacement for my goals?